The FDA has announced its approval of the first injectable extended-release regimen for adults who have HIV-1 infections. For patients who m...
The FDA has announced its approval of the first injectable extended-release regimen for adults who have HIV-1 infections. For patients who meet the criteria for the regimen, Cabenuva can reduce the number of dosing days to only 12 per year, according to ViiV Healthcare, which says the regimen can replace antiretroviral regimens in eligible adults. According to ViiV Healthcare, Cabenuva … Continue readingfrom SlashGear https://ift.tt/395xzeQ
via IFTTT
COMMENTS